Abstract:Objective To evaluate the effect and safety of modest tacrolimus(FK506) reduction by programming renal biospies.Methods A prospective,randomized,open study was designed and forty-eight recipients undergoing firstly cadaveric renal transplantation were divided randomly into two groups: low dose tacrolimus group(Lo-FK506 group,n=24) and standard dose tacrolimus group(St-FK506 group,n=24).The recipients in both groups were treated with triple immunosuppression regimen including mycophenolate mofetil(MMF),FK506 and adrenal cortex hormone.The FK506 blood trough concentration of St-FK506 group was maintained at 10-12 ng/ml in the first three months after study entry,and then at 8-10 ng/ml after three months.The FK506 blood trough concentration of Lo-FK506 group was maintained at 8-10 ng/ml in the first two months after study entry,3-7 ng/ml in third month,3-5 ng/ml after 3 months.All patients were followed up for one year.The FK506 blood trough concentration,renal function[serum creatinine(Scr),endogenous creatinine clearance rate(Ccr)],fasting blood glucose,glycosylated hemoglobin,seralbumin and blood fat were examined and recorded regularly.At the same time,acute rejection(AR) occurrence,pathological damage index score and chronic allograft damage index(CADI)of recipients were evaluated by using renal graft biopsy(FNA) at month 3 and 12 post-transplantation.The 1-year survival rate of patients /grafts and the incidence of adverse event were observed.Results One year follow-up post-transplantation,FK506 blood trough concentration in the Lo-FK506 group was lower compared with St-FK506 group(P<0.01),but most of the patients reached the target level.The level of Ccr in Lo-FK506 group was higher than that of St-FK506 group[(83±14) ml / min vs(62 ±16) ml/min,P<0.05].The level of glucose was lower in Lo-FK506 group than that of St-FK506 group(P<0.05).According to the results of programming renal biopsies,interstitial fibrosis,tubular atrophy and glomerulosclerosis score were also lower in Lo-FK506 group(all in P<0.05).The incidence,severity of AR as well as 1-year survival rates of patient /graft was similar in both groups(P>0.05).The incidence of pulmonary infection and de novo diabetes one year posttransplant was significantly lower in Lo-FK506 group compared with St-FK506 group(P<0.05 and P<0.01 respectively).Conclusion It is reliable and helpful to evaluate the efficacy of modest tacrolimus reduction by programming renal biopsies and to find the chronic pathological changes of transplanted grafts.Modest reduction of the FK506 blood trough concentration in the early stage after transplantation is good for kidney grafts and recipients without increasing the risk of rejection.

Role of FK506 Binding Protein on Tacrolimus Distribution in Red Blood Cells

Distribution and Protein Binding of FK506, a Potent Immunosuppressive Macrolide Lactone, in Human Blood and Its Uptake by Erythrocytes

Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats

A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis

FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506

Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters

Tacrolimus inhibits NF-κB activity and lymphotactin gene expression after heart transplantation in mouse

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue

Effect of Kaempferol on Tacrolimus-Induced Nephrotoxicity and Calcineurin B1 Expression Level in Animal Model

Influence of Genetic Polymorphisms on the Pharmacokinetics of Tacrolimus in Patients with Organ Transplantation

Enhancement by FK506 of Triptolide-induced Inhibition of Expression of COX-2 and Inos in Human Rheumatoid Arthritis Synovial Fibroblasts

Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality

Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients

P-glycoprotein, FK-binding Protein-12, and the Intracellular Tacrolimus Concentration in T-lymphocytes and Monocytes of Kidney Transplant Recipients

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells

FK506 promotes liver regeneration by suppressing natural killer cell activity

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report

Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits

A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients